Evidence map›Paper›PMID 42108270›Full record

Trial reportNature medicine2026

Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial.

D J van Veldhuisen, M Rienstra, A Mosterd, M Alings, A A Voors, K Damman, A D I van Asselt, M L Bouvy, J Schaap, E E van der Wall and 28 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. [Digitalis for heart failure: welcome back?]Innere Medizin (Heidelberg, Germany) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

D J van VeldhuisenDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
M RienstraDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0002-2581-070X
A MosterdDepartment of Cardiology, Meander Medical Center, Amersfoort, The Netherlands.ORCID http://orcid.org/0000-0002-6906-2643
M AlingsDepartment of Cardiology, Amphia Hospital, Breda, The Netherlands.
A A VoorsDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0002-5417-4415
K DammanDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0003-0190-2228
A D I van AsseltDepartment of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands.
M L BouvyDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
J SchaapDepartment of Cardiology, Amphia Hospital, Breda, The Netherlands.ORCID http://orcid.org/0009-0006-6646-8070
E E van der WallDepartment of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
H J G M CrijnsMaastricht University Medical Center, Maastricht, The Netherlands.ORCID http://orcid.org/0000-0003-1073-5337
D J TouwDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0002-1429-4789
P A M HoogslagDepartment of Cardiology, Isala Hospital Meppel, Meppel, The Netherlands.
J E C van de SwaluwDepartment of Cardiology, Beatrix Hospital Gorinchem, Gorinchem, The Netherlands.
R J SchuurmanDepartment of Cardiology, Treant Hospital Emmen, Emmen, The Netherlands.
A van der SluisDepartment of Cardiology, Deventer Hospital, Deventer, The Netherlands.
O BondarenkoDepartment of Cardiology, Frisius Medical Center, Leeuwarden, The Netherlands.
T J RömerDepartment of Cardiology, Alrijne Hospital Leiderdorp, Leiderdorp, The Netherlands.
T OosterhofDepartment of Cardiology, Hospital Gelderse Vallei, Ede, The Netherlands.
G L BartelsDepartment of Cardiology, Martini Hospital, Groningen, The Netherlands.
S KoudstaalDepartment of Cardiology, Green Heart Hospital, Gouda, The Netherlands.
P A DijkmansDepartment of Cardiology, Zaans Medical Center, Zaandam, The Netherlands.
G C M LinssenDepartment of Cardiology, Zorggroep Twente, Almelo, The Netherlands.ORCID http://orcid.org/0000-0002-3339-1955
I AksoyDepartment of Cardiology, Admiral De Ruyter Hospital, Goes, The Netherlands.
H G R DormanDepartment of Cardiology, Bravis Hospital, Bergen op Zoom, The Netherlands.
A SchutWorkgroup Cardiology Centers, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0001-9397-7109
M E W HemelsRijnstate Hospital, Arnhem, The Netherlands.
R G TielemanDepartment of Cardiology, Martini Hospital, Groningen, The Netherlands.
D J A LokDepartment of Cardiology, Deventer Hospital, Deventer, The Netherlands.
I C D WestendorpDepartment of Cardiology, Red Cross Hospital, Beverwijk, The Netherlands.
M A T VijverDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
G H D VoordesDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
A H de VosDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
E L Maas-SoerDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
D PostmusDepartment of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands.
G LunterDepartment of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0002-3798-2058
J G P TijssenDepartment of Cardiology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
P van der MeerDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. p.van.der.meer@umcg.nl.ORCID http://orcid.org/0000-0002-9705-4413

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Digoxin is the oldest drug in cardiovascular medicine, but its value in the current management of heart failure is unclear. Earlier studies have suggested that low-dose digoxin might be beneficial, but evidence from rigorous randomized clinical trials is lacking. In this double-blind, placebo-controlled trial (the DECISION trial), 1,001 patients with symptomatic chronic heart failure and a left ventricular ejection fraction of 50% or less were randomized to low-dose digoxin or placebo, with a target serum digoxin concentration of 0.5-0.9 ng ml

Indexed as

Cardiotonic AgentsDigoxinHeart FailureStroke VolumeAgedAged, 80 and overDouble-Blind MethodFemaleHumansMaleTreatment OutcomeCardiotonic AgentsDigoxin

Identifiers

PMID42108270
PMCPMC13375525

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.